Symptom Cluster Research in Women with Breast Cancer: A Comparison of Three Subgrouping Techniques

Angela R. Starkweather^1*, Debra E. Lyon¹, R. K. Elswick Jr.¹, Alison Montpetit¹, Yvette Conley², Nancy L. McCain¹

¹School of Nursing, Virginia Commonwealth University, Richmond, USA.
²School of Nursing, University of Pittsburgh, Pittsburgh, USA.

DOI: 10.4236/abcr.2013.24018                

Abstract

Aims: To examine how symptom cluster subgroups defined by extreme discordant composite scores, cut-off scores, or a median split influence statistical associations with peripheral cytokine levels in women with breast cancer. Background: Systemic cytokine dysregulation has been posited as a potential biological mechanism underlying symptom clusters in women with breast cancer. Symptom characteristics may play an important role in identifying cytokines of significant etiological importance, however, there is no consensus regarding to the ideal subgrouping technique to use. Design: A secondary analysis of data collected from a cross-sectional descriptive study of women with stage I-II breast cancer was used to examine and compare the relationships between peripheral cytokine levels and symptom subgroups defined by extreme discordant composite scores, cut-off scores, or a median split. Methods: Participant symptom scores were transformed into a composite score to account for variability in symptom intensity, frequency and interference. Cytokine levels in subgroups defined by composite scores within the highest and lowest 20% were contrasted with those composed from cut-off scores and a median split. Results: Subgroups defined by the composite score or cut-off scores resulted in similar statistical relationships with cytokine levels in contrast to the median split technique. The use of a median split for evaluating relationships between symptoms clusters and cytokine levels may increase the risk of a type I error. Conclusion: Composite and cut-off scores represent best techniques for defining symptom cluster subgroups in women with breast cancer. Using a consistent approach to define symptom clusters across studies may assist in identifying relevant biological mechanisms.

Keywords

Breast Neoplasms; Cluster Analysis; Symptom Clusters; Psychoneurological Symptoms

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	American Cancer Society, “Cancer Facts and Figures, 2013,” American Cancer Society, Atlanta, 2013.
[2]	C. M. Bender, F. Senuzen Ergun, M. Q. Rosenzweig, S. M. Cohen and S. M. Sereika, “Symptom Clusters in Breast Cancer across 3 Phases of the Disease,” Cancer Nursing, Vol. 28, No. 3, 2005, pp. 219-225. http://dx.doi.org/10.1097/00002820-200505000-00011
[3]	K. L. Byar, A. M. Berger, S. L. Bakken and M. A. Cetak, “Impact of Adjuvant Breast Cancer Chemotherapy on Fatigue, Other Symptoms, and Quality of Life,” Oncology Nursing Forum, Vol. 33 No. 1, 2006, pp. E18-E26. http://dx.doi.org/10.1188/06.ONF.E18-E26
[4]	E. Kim, T. Jahan, B. E. Aouizerat, M. J. Dodd, B. A. Cooper, S. M. Paul, C. West, K. Lee, P. S. Swift, W. Wara and C. Miaskowski, “Differences in Symptom Clusters Identified Using Occurrence Rates versus Symptom Severity Rating in Patients at the End of Radiation Therapy,” Cancer Nursing, Vol. 32, No. 6, 2009, pp. 429-436. http://dx.doi.org/10.1097/NCC.0b013e3181b046ad
[5]	J. A. Roscoe, G. R. Morrow, J. T. Hickok, P. Bushunow, S. Matteson, D. Rakita and P. L. Andrews, “Temporal Interrelationships among Fatigue, Circadian Rhythm and Depression in Breast Cancer Patients Undergoing Chemotherapy Treatment,” Supportive Care in Cancer, Vol. 10, No. 4, 2002, pp. 329-336. http://dx.doi.org/10.1007/s00520-001-0317-0
[6]	C. Miaskowski, B. A. Cooper, S. M. Paul, M. Dodd, K. Lee, B. E. Aouizerat, C. West, M. Cho and A. Bank, “Subgroups of Patients with Cancer with Different Symptom Experiences and Quality-of-Life Outcomes: A Cluster Analysis,” Oncology Nursing Forum, Vol. 33, No. 5, 2006, pp. E79-E89. http://dx.doi.org/10.1188/06.ONF.E79-E89
[7]	H. J. Kim, A. M. Barsevick and L. Tulman, “Predictors of the Intensity of Symptoms in a Cluster in Patients with Breast Cancer,” Journal of Nursing Scholarship, Vol. 41, No. 2, 2009, pp. 158-165. http://dx.doi.org/10.1111/j.1547-5069.2009.01267.x
[8]	L. Liu, L. Fiorentino, L. Natarajan, B. A. Parker, P. J. Mills, G. Robins Sadler, J. E. Dimsdale, M. Rissling, F. He and S. Ancoli-Israel, “Pre-Treatment Symptom Cluster in Breast Cancer Patients Is Associated with Worse Sleep, Fatigue and Depression during Chemotherapy,” Psychooncology, Vol. 18, No. 2, 2009, pp. 187-194. http://dx.doi.org/10.1002/pon.1412
[9]	O. G. Palesh, K. Collie, D. Batiuchok, J. Tilston, C. Koopman, M. L. Perlis, L. D. Butler, R. Carlson and D. Spiegel, “A Longitudinal Study of Depression, Pain, and Stress as Predictors of Sleep Disturbance among Women with Metastatic Breast Cancer,” Biological Psychology, Vol. 75, No. 1, 2007, pp. 37-44. http://dx.doi.org/10.1016/j.biopsycho.2006.11.002
[10]	W. K. W. So, G. March, W. M. Ling, F. Y. Leung, J. C. K. Lo, M. Yeung and G. K. H. Li, “The Symptom Cluster of Fatigue, Pain, Anxiety, and Depression and the Effect on the Quality of Life of Women Receiving Treatment for Breast Cancer: A Multicenter Study,” Oncology Nursing Forum, Vol. 36, No. 4, 2009, pp. E205-E214. http://dx.doi.org/10.1188/09.ONF.E205-E214
[11]	C. K. Gwede, B. J. Small, P. N. Munster, M. A. Andrykowski and P. B. Jacobsen, “Exploring the Differential Experience of Breast Cancer Treatment-Related Symptoms: A Cluster Analytic Approach,” Supportive Care in Cancer, Vol. 16, No. 8, 2008, pp. 925-933. http://dx.doi.org/10.1007/s00520-007-0364-2
[12]	M. J. Dodd, M. H. Cho, B. A. Cooper and C. Miaskowski, “The Effect of Symptom Clusters on Functional Status and Quality of Life in Women with Breast Cancer,” European Journal of Oncology Nursing, Vol. 14, No. 1, 2010, pp. 101-110. http://dx.doi.org/10.1016/j.ejon.2009.09.005
[13]	H. J. Kim, A. M. Barsevick, L. Tulman and P. A. McDermott, ”Treatment-Related Symptom Clusters in Breast Cancer: A Secondary Analysis,” Journal of Pain and Symptom Management, Vol. 36, No. 5, 2008, pp. 468-479. http://dx.doi.org/10.1016/j.jpainsymman.2007.11.011
[14]	C. S. Cleeland, G. J. Bennett, R. Dantzer, P. M. Dougherty, A. J. Dunn, C. A. Myers, A. H. Miller, R. Payne, J. M. Reuben, X. S. Wang and B. N. Lee, “Are the Symptoms of Cancer and Cancer Treatment Due to a Shared Biological Mechanism? A Cytokine-Immunologic Model of Cancer Symptoms,” Cancer, Vol. 97, No. 11, 2003, pp. 2919-2925. http://dx.doi.org/10.1002/cncr.11382
[15]	D. E. Lyon, N. L. McCain, J. Walter and C. Schubert, “Cytokine Comparisons between Women with Breast Cancer and Women with a Negative Breast Biopsy,” Nursing Research, Vol. 57, No. 1, 2008, pp. 51-58. http://dx.doi.org/10.1097/01.NNR.0000280655.58266.6c
[16]	J. Illi, C. Miaskowski, B. Cooper, J. D. Levine, L. Dunn, C. West, M. Dodd, A. Dhruva, S. M. Paul, C. Baggott, J. Cataldo, D. Langford, B. Schmidt and B. E. Aouizerat, “Association between Proand Anti-Inflammatory Cytokine Genes and a Symptom Cluster of Pain, Fatigue, Sleep Disturbance, and Depression,” Cytokine, Vol. 58, No. 2, 2012, pp. 437-447. http://dx.doi.org/10.1016/j.cyto. 2012.02.015
[17]	L. E. Carlson, T. S. Campbell, S. N. Garland and P. Grossman, “Associations among Salivary Cortisol, Melatonin, Catecholamines, Sleep Quality and Stress in Women with Breast Cancer and Health Controls,” Journal of Behavioral Medicine, Vol. 30, No. 1, 2007, pp. 45-58. http://dx.doi.org/10.1007/ s10865-006-9082-3
[18]	L. M. Thornton, B. L. Andersen and W. P. Blakely, “The Pain, Depression, and Fatigue Symptom Cluster in Advanced Breast Cancer: Covariation with the Hypothalamic-Pituitary-Adrenal Axis and the Sympathetic Nervous System,” Health Psychology, Vol. 29, No. 3, 2010, pp. 333-337.
[19]	L. T. Guey, J. Kravic, O. Melander, N. P. Burtt, J. M. Laramie, V. Lyssenko, A. Jonsson, E. Lindholm, T. Tuomi, S. Isomaa, P. Nilsson, P. Almgren, S. Kathiresan, L. Groop, A. B. Seymour, D. Altshuler and B. F. Voight, “Power in the Phenotypic Extremes: A Simulation Study of Power in discovery and Replication of Rare Variants,” Genetic Epidemiology, Vol. 35, No. 4, 2011, pp. 236-246.
[20]	R. Day, P. A. Ganz, J. P. Constantion, W. M. Cronin, D. L. Wickherham and B. Fisher, “Health-Related Quality of Life and Tamoxifen in Breast Cancer Prevention: A Report from the National Surgical Adjuvant Breast and Bowel Project P-1 Study,” Journal of Clinical Oncology, Vol. 17, No. 9, 1999, pp. 2659-2669.
[21]	L. S. Radloff, “The CES-D Scale: A Self-Report Depression Scale for Research in the General Population,” Applied Psychological Measurement, Vol. 1, No. 3, 1977, pp. 385-401. http://dx.doi.org/ 10.1177/014662167700100306
[22]	A. Caraceni, “Evaluation and Assessment of Cancer Pain and Cancer Pain Treatment,” Acta Anaesthesiologia Scandinavia, Vol. 45, No. 9, 2001, pp. 1067-1075. http://dx.doi.org/10.1034/j.1399-6576.2001.450903.x
[23]	R. Day, P. A. Ganz and J. P. Constantino, “Tamoxifen and Depression: More Evidence from the National Surgical Adjuvant Breast and Bowel Project’s Breast Cancer Prevention (P-1) Randomized Study,” Journal of the National Cancer Institute, Vol. 93, No. 21, 2001, pp. 1615-1623. http://dx.doi.org/10.1093/jnci/93.21.1615
[24]	J. A. Roscoe, G. R. Morrow, J. T. Hickok, K. M. Mustian, J. J. Griggs, S. E. Matteson, P. Bushunow, R. Qazi and B. Smith, “Effect of Paroxetine Hydrochloride (Paxil) on Fatigue and Depression in Breast Cancer Patients Receiving Chemotherapy,” Breast Cancer Research and Treatment, Vol. 89, No. 3, 2005, pp. 243-249. http://dx.doi.org/10.1007/s10549-004-2175-1